

Stakeholder Insight: Osteoarthritis - Drug development lags behind rising osteoarthritis population

<https://marketpublishers.com/r/SF55D4281A0EN.html>

Date: December 2009

Pages: 205

Price: US\$ 15,200.00 (Single User License)

ID: SF55D4281A0EN

Abstracts

Introduction

Datamonitor expect osteoarthritis prevalence to grow by over 10 million by 2020, owing mainly to an aging population. In the near-term the approach to treatment will remain constant, with improved side-effects dominating the unmet needs. However, therapies which target the underlying causes of osteoarthritis have the potential to reshape osteoarthritis treatment.

Scope

*Snapshot of the osteoarthritis market based on a survey of 180 rheumatologists/primary care physicians, with views from key opinion leader interviews

*Analysis of osteoarthritis epidemiology, with future projections of prevalence and patient numbers to 2020

*Overview of treatment options at the class and molecule level, as well as treatment outcome analysis

*Assessment of treatment satisfaction, unmet needs and physicians' awareness of key pipeline therapies

Highlights

The estimated diagnosis rate of 55% reflects a lack of treatment-seeking by mild

sufferers of the disease, who often resort to self-medication. This equates to nearly 37 million undiagnosed patients in 2009 and with a predicted rise in osteoarthritis numbers this is a market with growth potential.

Pain-relieving drugs, particularly, oral non-steroidal anti-inflammatory drugs (NSAIDs) are the foundation of pharmacological therapy in osteoarthritis. Physicians continue to be concerned over NSAID toxicity, with three-quarters of severe patients who are receiving NSAIDs currently co-prescribed a gastroprotectant.

Physicians are generally unsatisfied with current osteoarthritis pharmacological treatments. A clear need for alternative drugs exists to treat this prevalent condition. 41% of physicians ranked disease modifying osteoarthritis drugs (DMOADs) as the highest unmet need, but the majority of physicians estimate that DMOADs are 8 years from the market.

Reasons to Purchase

*Understand current therapy trends for the major drug classes used in osteoarthritis split by disease severity and assess unmet needs in the disease

*Validate new product forecasting based on diagnosis rates and treatment by patient segmentation and drug class

*Use the interactive Excel model of treatment trees and patient numbers to estimate the osteoarthritis population in each of the seven major markets

Contents

ABOUT DATAMONITOR HEALTHCARE

About the Immunology and Inflammation pharmaceutical analysis team

CHAPTER 1 EXECUTIVE SUMMARY

Scope of the analysis
Datamonitor insight into the osteoarthritis market
Contributing experts
Related reports
Upcoming related reports

CHAPTER 2 INTRODUCTION AND SCOPE

Coverage of the Stakeholder Insight Survey
Epidemiology and patient segmentation in osteoarthritis
Treatment options and guidelines
Improving treatment outcomes
Future trends

CHAPTER 3 COUNTRY TREATMENT TREES

Introduction to treatment trees
US
Japan
France
Germany
Italy
Spain
UK

CHAPTER 4 EPIDEMIOLOGY AND PATIENT SEGMENTATION

Definition and classification of osteoarthritis
Primary (idiopathic) osteoarthritis
Secondary osteoarthritis
Epidemiology of osteoarthritis

Stakeholder Insight: Osteoarthritis - Drug development lags behind rising osteoarthritis population

Datamonitor estimates 81.4 million osteoarthritis sufferers in the seven major markets in 2009

Measures used to determine radiographic and clinical osteoarthritis

American College of Rheumatology (ACR) criteria

Kellgren-Lawrence scale

Epidemiological studies of osteoarthritis

Assumptions and caveats

US

Japan

Europe

France and Germany

Italy

Spain

UK

Changes in the osteoarthritis population

Additional international osteoarthritis epidemiology studies

Co-morbidities and risk factors in osteoarthritis

Co-morbidities in patients with osteoarthritis are common

Obesity, hypertension and high cholesterol, are the most common co-morbidities present in osteoarthritis patients

High prevalence of cardiovascular, endocrinology and pulmonary co-morbidities in osteoarthritis

Gastrointestinal co-morbidities in osteoarthritis

Previous trauma of the joint is the most common musculoskeletal co-morbidity in osteoarthritis

Central nervous system co-morbidities; depression is highly prevalent in osteoarthritis

Co-morbidities associated with lifestyle factors in osteoarthritis patients

Other co-morbidities present in osteoarthritis patients

Risk factors and patient-group segmentation are critical to osteoarthritis definition

Age

Gender

Mechanical stress

Obesity

Presentation and diagnosis

Diagnosis of osteoarthritis

Techniques for diagnosis

Diagnosis rates

Severity of osteoarthritis

Definition of each level of severity of osteoarthritis provided by Datamonitor to

physicians surveyed

CHAPTER 5 TREATMENT OPTIONS AND GUIDELINES

Treatment guidelines

Several guidelines exist for the treatment of osteoarthritis

American College of Rheumatology (ACR)

European League Against Rheumatism (EULAR)

National Institute for Health and Clinical Excellence (NICE)

Osteoarthritis Research Society International (OARSI)

Treatment options

Pharmacological versus non-pharmacological treatment

Non-pharmacological treatment of osteoarthritis

Weight loss and weight control is an effective and common tactic

Nutraceuticals - divided opinion on their use in osteoarthritis treatment

Exercise aids in reducing pain

Other non-pharmacological treatment options

Pharmacological treatment of osteoarthritis

Several drug classes are used in the treatment of osteoarthritis

Analgesics

Non-steroidal anti-inflammatory drugs and COX-2 inhibitors

Branded versus generic drug use

Variations exist in the use of branded versus generic drugs in osteoarthritis treatment in the seven major markets

CHAPTER 6 IMPROVING TREATMENT OUTCOMES

Treatment outcomes and satisfaction

Efficacy assessment

Measuring disease activity in osteoarthritis patients

Communication between the patient and physician is the most common method of assessing treatment efficacy in osteoarthritis

Physicians allow an average of five months to assess treatment efficacy in their osteoarthritis patients

Osteoarthritis patients usually require joint surgery after 7-8 years

Physicians are generally unsatisfied with current pharmacological treatment for osteoarthritis

Unmet needs

Disease modifying osteoarthritis drugs is the highest unmet need in osteoarthritis

Other unmet needs in osteoarthritis

Disease modifying osteoarthritis drugs (DMOADs)

Most physicians believe DMOAD development is possible

DMOADs are up to 8 years from reaching the market

Challenges in clinical study design for DMOADs

It is important for DMOADs to show both disease modification and pain relief in clinical trials

Matrix-metalloproteinase (MMP) inhibitors are the most important molecular target for DMOAD

Pipeline products

Eli Lilly's Cymbalta (duloxetine) is the late-stage drug therapy which most physicians are aware of

Caveat of physicians' awareness to drug therapies

Cymbalta (duloxetine; Eli Lilly)

Synvisc-One (hylan G-F 20; Genzyme)

Naproxcinod (NicOx)

Tanezumab (Pfizer)

Vimovo (PN-400; naproxen plus esomeprazole; Pozen, AstraZeneca)

Fentora (fentanyl; Cephalon)

Diractin (ketoprofen; Idea AG/Alpharma)

BIBLIOGRAPHY

Journal papers

Websites

Datamonitor reports

APPENDIX A

Physician research methodology

Physician sample breakdown

APPENDIX B

The survey questionnaire

Diagnosis and patient segmentation

Treatment

Unmet needs

Treatment outcomes and Prescribing patterns

[About Datamonitor](#)

[About Datamonitor Healthcare](#)

[About the Immunology & Inflammation analysis team](#)

[Disclaimer](#)

List Of Tables

LIST OF TABLES

Table 1: Estimated adult osteoarthritis populations in the seven major markets, split by sex and age group, 2009

Table 2: Epidemiological studies of osteoarthritis in the seven major markets, 1984-2009

Table 3: US osteoarthritis population by age group and gender, 2009

Table 4: US gender-specific prevalence of radiographic and symptomatic osteoarthritis in different anatomical sites, 2008

Table 5: Estimated adult osteoarthritis population in Japan by age and gender, 2009

Table 6: Estimated adult osteoarthritis population in five major EU markets by age and gender, 2009

Table 7: Spanish EPISER study showing prevalence of knee and hand osteoarthritis, 2008

Table 8: Combined sample of northern England studies, radiographic knee osteoarthritis by age and gender

Table 9: Datamonitor's future projection of the adult osteoarthritis population in the seven major markets, 2010- 2020

Table 10: International epidemiological studies on osteoarthritis prevalence, 2001-09

Table 11: Mean percentages of the co-morbidities suffered by osteoarthritis patients in the seven major markets (%), 2009

Table 12: Association between doctor-diagnosed* arthritis and body mass index from the BFRSS study, 2009

Table 13: Mean percentage of osteoarthritis patients suffering from cardiovascular, endocrinology and pulmonary co-morbidities (%), 2009

Table 14: Mean percentages of gastrointestinal co-morbidities suffered by osteoarthritis patients in the seven major markets (%), 2009

Table 15: Percentage of osteoarthritis patients diagnosed by primary care physicians versus rheumatologists (%), 2009

Table 16: Mean percentage of osteoarthritis patients receiving each type of therapy across the seven major markets, 2009

Table 17: Mean percentage of osteoarthritis patients receiving oral NSAIDs in the seven major markets (%), 2009

Table 18: Osteoarthritis patients receiving oral NSAIDs split by molecule and disease severity in the seven major markets (%), 2009

Table 19: Mild osteoarthritis patients receiving oral NSAIDs split by molecule in the seven major markets (%), 2009

Table 20: Moderate osteoarthritis patients receiving oral NSAIDs split by molecule in the seven major markets (%), 2009

Table 21: Severe osteoarthritis patients receiving oral NSAIDs split by molecule in the seven major markets (%), 2009

Table 22: Osteoarthritis patients receiving oral NSAIDs a gastroprotectant in the seven major markets (%), 2009

Table 23: Mean percentage of osteoarthritis patients receiving topical NSAIDs in the seven major markets (%), 2009

Table 24: Osteoarthritis patients receiving a topical NSAID by molecule in the seven major markets (%), 2009

Table 25: Mild osteoarthritis patients receiving a topical NSAID by molecule in the seven major markets (%), 2009

Table 26: Moderate osteoarthritis patients receiving a topical NSAID by molecule in the seven major markets (%), 2009

Table 27: Severe osteoarthritis patients receiving a topical NSAID by molecule in the seven major markets (%), 2009

Table 28: Osteoarthritis patients receiving a cyclo-oxygenase-2 (COX-2) inhibitor by molecule and disease severity in the seven major markets(%), 2009

Table 29: Osteoarthritis patients receiving injectable hyaluronic acids split by physician type and disease severity in the seven major markets (%), 2009

Table 30: Hyaluronic acid brands most commonly prescribed by physicians in the seven major markets (n; %), 2009

Table 31: Number of physicians who use each outcome measure in the seven major markets (n), 2009

Table 32: Priority ranking allocated by physicians to unmet needs in the treatment of osteoarthritis in the seven major markets, 2009

Table 33: Physician opinion of promising molecular targets for disease-modifying osteoarthritis drugs (DMOADs), in the seven major markets, 2009

Table 34: Primary care physicians' and rheumatologists' response to promising molecular targets for disease-modifying osteoarthritis drugs (DMOADs), 2009

Table 35: Physicians' awareness of drugs in development for osteoarthritis in the seven major markets, 2009

Table 36: Physicians surveyed regarding osteoarthritis, 2009

List Of Figures

LIST OF FIGURES

Figure 1: US osteoarthritis patient population, split by physician-estimated diagnosis, disease severity, drug-treated population and drug-class usage, 2009

Figure 2: Japan osteoarthritis patient population, split by physician-estimated diagnosis, disease severity, drug-treated population and drug-class usage

Figure 3: France osteoarthritis patient population, split by physician-estimated diagnosis, disease severity, drug-treated population and drug-class usage, 2009

Figure 4: Germany osteoarthritis patient population, split by physician-estimated diagnosis, disease severity, drug-treated population and drug-class usage, 2009

Figure 5: Italy osteoarthritis patient population, split by physician-estimated diagnosis, disease severity, drug-treated population and drug-class usage, 2009

Figure 6: Spain osteoarthritis patient population, split by physician-estimated diagnosis, disease severity, drug-treated population and drug-class usage, 2009

Figure 7: UK osteoarthritis patient population, split by physician-estimated diagnosis, disease severity, drug-treated population and drug-class usage, 2009

Figure 8: Adult osteoarthritis population in the seven major markets, 2009

Figure 9: Estimated adult osteoarthritis population in five major EU markets, by age and gender, 2009

Figure 10: Datamonitor's future projection of the adult osteoarthritis population, split by age group, in the seven major markets, 2010- 2020

Figure 11: Datamonitor future projection of the adult osteoarthritis population, split by region, in the seven major markets, 2010- 2020

Figure 12: Datamonitor future projection of the 65 years and older osteoarthritis population in Japan, 2010- 2020

Figure 13: Mean percentages of osteoarthritis patients suffering from a co-morbidity in the seven major markets (%), 2009

Figure 14: Cardiovascular, endocrinology and pulmonary co-morbidities suffered by osteoarthritis patients in the seven major markets (%), 2009

Figure 15: Gastrointestinal co-morbidities in osteoarthritis patients in the seven major markets (%), 2009

Figure 16: Musculoskeletal co-morbidities in osteoarthritis patients in the seven major markets (%), 2009

Figure 17: Central nervous system co-morbidities in osteoarthritis patients in the seven major markets (%), 2009

Figure 18: Lifestyle factors commonly present in osteoarthritis patients in the seven major markets (%), 2009

Figure 19: Other co-morbidities that 10% or more of osteoarthritis patients suffer from in the seven major markets (%), 2009

Figure 20: Techniques used in the diagnosis of osteoarthritis sufferers in the seven major markets, 2009

Figure 21: Percentage of osteoarthritis patients diagnosed versus undiagnosed in the seven major markets (%), 2009

Figure 22: Percentage of osteoarthritis patients diagnosed by primary care physicians versus rheumatologists (%), 2009

Figure 23: Percentage of diagnosed osteoarthritis patients with mild, moderate or severe osteoarthritis, 2009

Figure 24: NICE clinical guidelines for the care and management of osteoarthritis in adults, 2008

Figure 25: Mean percentage of osteoarthritis patients receiving each type of therapy across the seven major markets, 2009

Figure 26: Mean percentage of osteoarthritis patients receiving a non-pharmacological therapy (%), 2009

Figure 27: Mean percentage of osteoarthritis patients receiving weight loss therapy split by physician type (%), 2009

Figure 28: Mean percentage of osteoarthritis patients receiving exercise therapy split by physician type in the seven major markets (%), 2009

Figure 29: Mean percentage of osteoarthritis patients receiving physical therapy split by physician type in the seven major markets (%), 2009

Figure 30: Mean percentage of osteoarthritis patients receiving a pharmacological therapy in the seven major markets (%), 2009

Figure 31: Mean percentage of osteoarthritis patients receiving simple analgesics in the seven major markets (%), 2009

Figure 32: Mean percentage of osteoarthritis patients receiving oral NSAIDs in the seven major markets (%), 2009

Figure 33: Osteoarthritis patients receiving oral NSAIDs split by molecule and disease severity in the seven major markets (%), 2009

Figure 34: Osteoarthritis patients receiving oral NSAIDs a gastroprotectant, split by disease severity in the seven major markets (%), 2009

Figure 35: Mean percentage of osteoarthritis patients receiving topical NSAIDs in the seven major markets (%), 2009

Figure 36: Osteoarthritis patients receiving a topical NSAID by molecule in the seven major markets (%), 2009

Figure 37: Percentage of osteoarthritis patients receiving a COX-2 (cyclooxygenase) inhibitor by molecule in the seven major markets (%), 2009

Figure 38: Percentage of osteoarthritis patients receiving a COX-2 (cyclooxygenase-2)

inhibitor continuously versus intermittently, 2009

Figure 39: Percentage of osteoarthritis patients receiving injectable hyaluronic acids by molecule in the seven major markets (%), 2009

Figure 40: Mean percentages of osteoarthritis patients receiving treatment with each drug class in the seven major markets (%), 2009

Figure 41: Mean percentages of osteoarthritis patients receiving treatment with each drug class by physician type in the seven major markets (%), 2009

Figure 42: Percentage of osteoarthritis patients in the US receiving branded versus generic treatment for each drug class (%), 2009

Figure 43: Percentage of osteoarthritis patients in Japan receiving branded versus generic treatment for each drug class (%), 2009

Figure 44: Percentage of osteoarthritis patients in France receiving branded versus generic treatment for each drug class (%), 2009

Figure 45: Percentage of osteoarthritis patients in Germany receiving branded versus generic treatment for each drug class (%), 2009

Figure 46: Percentage of osteoarthritis patients in Italy receiving branded versus generic treatment for each drug class (%), 2009

Figure 47: Percentage of osteoarthritis patients in Spain receiving branded versus generic treatment for each drug class (%), 2009

Figure 48: Percentage of osteoarthritis patients in the UK receiving branded versus generic treatment for each drug class (%), 2009

Figure 49: Outcome measures used by physicians to assess treatment efficacy in osteoarthritis patients in the seven major markets, 2009

Figure 50: Number of months needed to assess treatment efficacy in osteoarthritis patients in the seven major markets, 2009

Figure 51: Number of months needed to assess treatment efficacy in osteoarthritis patients by physician type in the seven major markets, 2009

Figure 52: Osteoarthritis patients who will eventually require joint surgery in the seven major markets (%), 2009

Figure 53: Average number of months between treatment initiation and joint surgery for osteoarthritis patients in the seven major markets, 2009

Figure 54: Physicians level of satisfaction with current pharmacological treatments for osteoarthritis in the seven major markets, 2009

Figure 55: Physicians' overall satisfaction with currently available pharmacological treatments for osteoarthritis in the seven major markets, 2009

Figure 56: Priority ranking allocated by physicians to unmet needs in the treatment of osteoarthritis, 2009

Figure 57: Physicians' response to whether or not it is possible to develop a disease-modifying osteoarthritis drug (DMOAD), 2009

Figure 58: Physicians' estimates of the time it will take for a disease-modifying osteoarthritis drug (DMOAD) to reach market, 2009

Figure 59: Physicians' rating on the importance that a disease-modifying osteoarthritis drug shows both disease modification and pain relief in clinical trial data (n), 2009

Figure 60: Physicians' response to promising molecular targets for disease-modifying osteoarthritis drugs (DMOADs) in the seven major markets, 2009

Figure 61: Physicians' awareness of drugs in development for osteoarthritis, 2009

Figure 62: Physicians' awareness of drugs in development for osteoarthritis in the seven major markets, 2009

Figure 63: Physicians' response to awareness of Synvisc-One for treatment of osteoarthritis in the seven major markets, 2009

I would like to order

Product name: Stakeholder Insight: Osteoarthritis - Drug development lags behind rising osteoarthritis population

Product link: <https://marketpublishers.com/r/SF55D4281A0EN.html>

Price: US\$ 15,200.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/SF55D4281A0EN.html>